文献速递自身免疫性与大疱性皮肤病

天疱疮患者利妥昔单抗一线治疗后短期复发的相关因素:随机临床试验的事后分析

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该事后分析基于RITUX 3随机临床试验,纳入47例新诊断天疱疮患者,分析利妥昔单抗一线治疗后12个月内复发的相关因素。结果显示基线PDAI评分较高及第3个月抗DSG1≥20 IU/mL和/或抗DSG3≥130 IU/mL与复发相关,联合标准对复发具有50%阳性预测值和94%阴性预测值。

要点

  • 基线PDAI评分≥45且第3个月抗DSG抗体持续高水平提示复发风险高。
  • 联合标准阳性预测值50%,阴性预测值94%,有助于识别低复发风险患者。
  • 低风险患者可能无需第6个月早期维持性利妥昔单抗输注。

核心结论

  • 基线PDAI评分和初始利妥昔单抗周期后抗DSG抗体变化可能帮助区分高复发风险与低复发风险患者。

研究设计与样本

  • RITUX 3随机临床试验的事后分析,纳入法国20个三级医疗中心皮肤科的47例新诊断天疱疮患者(平均年龄54.3岁,男性17例,女性30例)。

主要发现

  • PDAI≥45和/或第3个月抗DSG1≥20 IU/mL和/或抗DSG3≥130 IU/mL对复发的阳性预测值为50%(95%CI 27%-73%),阴性预测值为94%(95%CI 73%-100%)。

关键数值与推荐

  • 基线PDAI评分范围0-250分,≥45分定义为严重天疱疮。
  • 第3个月持续抗DSG1抗体≥20 IU/mL和/或抗DSG3抗体≥130 IU/mL视为持续阳性。

临床怎么用

  • 对基线PDAI≥45且第3个月抗DSG抗体持续高水平者,可考虑第6个月维持性利妥昔单抗输注。
  • 对联合标准阴性者(低复发风险),可能无需早期维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus. OBJECTIVE: To examine factors associated with short-term relapse in patients with pemphigus treated with rituximab. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial (Comparison Between Rituximab Treatment and Oral Corticosteroid Treatment in Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, to December 31, 2015, included patients from 20 dermatology departments of tertiary care centers in France from the RITUX 3 trial and 3 newly diagnosed patients treated according to the trial protocol. Data analysis was performed from February 1 to June 30, 2019. EXPOSURE: Patients randomly assigned to the rituximab group in the RITUX 3 trial and the 3 additional patients were treated with 1000 mg of intravenous rituximab on days 0 and 14 and 500 mg at months 12 and 18 combined with a short-term prednisone regimen. MAIN OUTCOMES AND MEASURES: Baseline (pretreatment) clinical and biological characteristics (Pemphigus Disease Area Index [PDAI] score, ranging from 0-250 points, with higher values indicating more severe disease) and changes in anti-desmoglein (DSG) 1 and anti-DSG3 values as measured by enzyme-linked immunosorbent assay during the 3 months after rituximab treatment were compared between patients with disease relapse and those who maintained clinical remission during the first 12 months after treatment. The positive and negative predictive values of these factors were calculated. RESULTS: Among 47 patients (mean [SD] age, 54.3 [17.0] years; 17 [36%] male and 30 [64%] female) included in the study, the mean (SD) baseline PDAI score for patients with relapsing disease was higher than that of the patients with nonrelapsing disease (54 [33] vs 28 [24]; P = .03). At month 3, 7 of 11 patients with relapsing disease (64%) vs 7 of 36 patients with nonrelapsing disease (19%) had persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher (P = .01). A PDAI score of 45 or higher defining severe pemphigus and/or persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher at month 3 provided a positive predictive value of 50% (95% CI, 27%-73%) and a negative predictive value of 94% (95% CI, 73%-100%) for the occurrence of relapse after rituximab. CONCLUSIONS AND RELEVANCE: The findings suggest that initial PDAI score and changes in anti-DSG antibody values after the initial cycle of rituximab might help differentiate a subgroup of patients with high risk of relapse who might benefit from maintenance rituximab infusion at month 6 from a subgroup of patients with low risk of relapse who do not need early maintenance therapy. TRIAL REGISTRATION: NCT00784589.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Mignard C, Maho-Vaillant M, Golinski ML, et al. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2020. PMID: 32186656. doi:10.1001/jamadermatol.2020.0290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。